RxDoctor Payments Data

Gregory Sutton, MD

Hematology & Oncology · Chattanooga, TNNPI 1255575270

Payments from drug & device makers

$5,323in general payments, 2019–2025

Across 231 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$397
  • AstraZeneca$395
  • Takeda Pharmaceuticals U.S.A., Inc.$268
  • Daiichi Sankyo Inc.$250
  • Astellas Pharma US Inc$230
  • Pfizer$227
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$5,27399%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,323 in reported general payments places this provider in the 35th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$5,004,055
Medicare patients
897
Services billed
181,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide79$1,308,902
NubeqaDarolutamide94$1,097,472
ImbruvicaIbrutinib43$707,353
IbrancePalbociclib45$673,702
XtandiEnzalutamide41$533,227
LenvimaLenvatinib Mesylate21$509,688
CabometyxCabozantinib S-Malate23$477,560
CalquenceAcalabrutinib Maleate21$316,365
PomalystPomalidomide13$263,732
TagrissoOsimertinib Mesylate16$245,883
SprycelDasatinib19$208,008
VerzenioAbemaciclib14$205,884
PromactaEltrombopag Olamine11$185,629
TasignaNilotinib Hcl17$171,039
Abiraterone Acetate73$137,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$40$1,308,90279 claims
BayerNubeqa$113$1,097,47294 claims
PfizerIbrance, Eliquis$227$699,52288 claims
AstraZenecaCalquence, Tagrisso$395$562,24837 claims
Astellas Pharma US IncXtandi$230$533,22741 claims
Eisai Inc.Lenvima$102$509,68821 claims
Exelixis Inc.Cabometyx$182$477,56023 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$95$471,74032 claims
NovartisPromacta, Tasigna$397$356,66828 claims
Lilly USA, LLCVerzenio, Olanzapine$145$206,44078 claims
Johnson & JohnsonXarelto$178$16,81615 claims
AmgenAranesp$13$16,71612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 251 hematology & oncology providers in Tennessee.

Other hematology & oncology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →